Literature DB >> 15188367

Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis.

Philip J Clements1, Jonathan G Goldin, Eric C Kleerup, Daniel E Furst, Robert M Elashoff, Donald P Tashkin, Michael D Roth.   

Abstract

OBJECTIVE: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Although early identification and treatment of alveolitis may prevent deterioration of lung function, the best approach for diagnosing active alveolitis remains controversial. This study was undertaken to investigate the utility of high-resolution computed tomography (HRCT) of the chest, in comparison with bronchoalveolar lavage (BAL), in the diagnosis of alveolitis in these patients.
METHODS: Eighteen patients with SSc and dyspnea were evaluated for ILD by pulmonary function testing and bronchoalveolar lavage (BAL), and 15 of these patients underwent chest HRCT. BAL was performed in either the middle lobe or the lingula, and also in a lower lung segment. Differential cell counts were determined by clinical cytopathology, with retrospective recounting in a blinded manner by a single technician. Active alveolitis was defined as the presence of > or =3.0% polymorphonuclear cells and/or > or =2% eosinophils in BAL fluid. BAL fluids were cultured for bacteria, mycobacteria, and fungi. HRCT scans were evaluated in a blinded manner for ground-glass opacification and fibrosis in the lavaged lobes.
RESULTS: Nine of the 18 patients had active alveolitis recorded in both lavaged segments, while in 4 patients it was recorded in only 1 segment (lower lobe in 3). Following repeat differential cell counting, 3 patients were reclassified as having active alveolitis and 1 as having no alveolitis. Culture of BAL fluid identified clinically unsuspected infection in 3 patients. For the right middle lung lobe or lingula there was excellent agreement between ground-glass opacification and the finding of alveolitis on BAL from segments in the same lung regions, but this was not observed for the lower lobes. The correlation between fibrosis on HRCT and the presence of alveolitis on BAL was significant for the lower lobes but not the middle lung fields.
CONCLUSION: BAL of the middle lobe or lingula may underestimate the presence of active alveolitis. Similarly, while ground-glass opacification on HRCT accurately predicted alveolitis in the middle lung fields, HRCT did not detect all sites of inflammation and did not identify infectious etiologies. These data suggest that, in addition to HRCT, BAL with lavage, differential cell counting, and culture from at least 2 segments of lung be performed for diagnosing SSc alveolitis.

Entities:  

Mesh:

Year:  2004        PMID: 15188367     DOI: 10.1002/art.20265

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

Review 2.  [Therapy of systemic sclerosis].

Authors:  M Meurer; P Rehberger
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

3.  Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.

Authors:  Stefania Volpinari; Renato La Corte; Stefano Bighi; Franco Ravenna; Napoleone Prandini; Andrea Lo Monaco; Francesco Trotta
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

4.  Effect of segmental bronchoalveolar lavage on quantitative computed tomography of the lung.

Authors:  Luke M Gabe; Kimberly M Baker; Edwin J R van Beek; Gary W Hunninghake; Joseph M Reinhardt; Eric A Hoffman
Journal:  Acad Radiol       Date:  2011-07       Impact factor: 3.173

Review 5.  Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study.

Authors:  Kristin B Highland; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

6.  Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.

Authors:  Arthur C Theodore; Chi-Hong Tseng; Ning Li; Robert M Elashoff; Donald P Tashkin
Journal:  Chest       Date:  2012-09       Impact factor: 9.410

Review 7.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

8.  Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.

Authors:  Philip J Clements; Michael D Roth; Robert Elashoff; Donald P Tashkin; Jonathan Goldin; Richard M Silver; Mildred Sterz; James R Seibold; Dean Schraufnagel; Robert W Simms; Marcy Bolster; Robert A Wise; Virginia Steen; M D Mayes; Kari Connelly; Mark Metersky; Daniel E Furst
Journal:  Ann Rheum Dis       Date:  2007-05-07       Impact factor: 19.103

Review 9.  Scleroderma lung: pathogenesis, evaluation and current therapy.

Authors:  Jacob M van Laar; Jan Stolk; Alan Tyndall
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities.

Authors:  M Bellia; F Cannizzaro; N Scichilone; M Riili; G Triolo; M Midiri; R Lagalla
Journal:  Radiol Med       Date:  2009-03-05       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.